BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN

被引:28
|
作者
Deng, Rong [1 ]
Guo, Yanmin [1 ]
Li, Lian [1 ]
He, Jianfeng [1 ]
Qiang, Zhe [1 ]
Zhang, Hailong [1 ]
Chen, Ran [1 ]
Wang, Yanli [1 ]
Zhao, Xian [1 ,2 ]
Yu, Jianxiu [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, State Key Lab Oncogenes & Related Genes, Sch Med,Shanghai Key Lab Tumor Microenvironm &, Shanghai 200025, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Basic Clin Res Ctr, Sch Med, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
BAP1; cancer progression; deubiquitination; prostate cancer; PTEN; PREVENTS CHROMOSOME INSTABILITY; TUMOR-SUPPRESSOR; E3; LIGASE; CELL-PROLIFERATION; UBIQUITIN LIGASE; GENE; MUTATION; BREAST; COMPLEX; SUMOYLATION;
D O I
10.1002/1878-0261.12844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deubiquitinase BAP1 is an important tumor suppressor in several malignancies, but its functions and critical substrates in prostate cancer (PCa) remain unclear. Here, we report that the mRNA and protein expression levels of BAP1 are downregulated in clinical PCa specimens. BAP1 can physically bind to and deubiquitinate PTEN, which inhibits the ubiquitination-mediated degradation of PTEN and thus stabilizes PTEN protein. Ectopically expressed BAP1 in PCa cells increases PTEN protein level and subsequently inhibits the AKT signaling pathway, thus suppressing PCa progression. Conversely, knockdown of BAP1 in PCa cells leads to the decrease in PTEN protein level and the activation of the Akt signaling pathway, therefore promoting malignant transformation and cancer metastasis. However, these can be reversed by the re-expression of PTEN. More importantly, we found that BAP1 protein level positively correlates with PTEN in a substantial fraction of human cancers. These findings demonstrate that BAP1 is an important deubiquitinase of PTEN for its stability and the BAP1-PTEN signaling axis plays a crucial role in tumor suppression.
引用
收藏
页码:279 / 298
页数:20
相关论文
共 50 条
  • [21] Multiple BAP1 inactivated Naevi: sentinel markers of suspected germline BAP1 mutated cancer family
    Nestor, L.
    Aird, J.
    Coleman, R.
    Ormond, P.
    Leonard, N.
    Healy, C.
    Calonje, E.
    Gallagher, D.
    Kelleher, F.
    McMenamin, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 : 23 - 23
  • [22] Estimation of the timing of BAP1 mutation in uveal melanoma progression
    Uner, Ogul E.
    See, Thonnie Rose O.
    Szalai, Eszter
    Grossniklaus, Hans E.
    Stalhammar, Gustav
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] Estimation of the timing of BAP1 mutation in uveal melanoma progression
    Ogul E. Uner
    Thonnie Rose O. See
    Eszter Szalai
    Hans E. Grossniklaus
    Gustav Stålhammar
    Scientific Reports, 11
  • [24] BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
    Arzt, Lisa
    Quehenberger, Franz
    Halbwedl, Iris
    Mairinger, Thomas
    Popper, Helmut H.
    PATHOLOGY & ONCOLOGY RESEARCH, 2014, 20 (01) : 145 - 151
  • [25] Loss of Bap1 Expression in Non-Melanoma Skin Cancer in Patients With Germline BAP1 Mutations
    Mochel, Mark
    Piris, Adriano
    Nose, Vania
    Hoang, Mai
    MODERN PATHOLOGY, 2015, 28 : 124A - 124A
  • [26] Loss of Bap1 Expression in Non-Melanoma Skin Cancer in Patients With Germline BAP1 Mutations
    Mochel, Mark
    Piris, Adriano
    Nose, Vania
    Hoang, Mai
    LABORATORY INVESTIGATION, 2015, 95 : 124A - 124A
  • [27] BAP1 Loss in Triple Negative Breast Cancer
    Vougiouklakis, Theodore
    Schwartz, Christopher
    Cotzia, Paolo
    Snuderl, Matija
    Jour, George
    Darvishian, Farbod
    LABORATORY INVESTIGATION, 2019, 99
  • [28] A mechanism for the tissue specificity in BAP1 cancer syndrome
    Machida, Yuichi J.
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S621 - S624
  • [29] BAP1 in cancer: epigenetic stability and genome integrity
    Sabrina Caporali
    Alessio Butera
    Ivano Amelio
    Discover Oncology, 13
  • [30] Expanded detection and impact of BAP1 alterations in cancer
    Sturgill, Ian R.
    Raab, Jesse R.
    Hoadley, Katherine A.
    NAR CANCER, 2024, 6 (04):